Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

romidepsin 8Vincristine 6Cyclophosphamide 6Specimen Handling 5Rituximab 5Biopsy 5fludarabine 4Prednisone 4Methotrexate 4Magnetic Resonance Spectroscopy 4Lactones 4Doxorubicin 4Depsipeptides 4ruxolitinib 3duvelisib 3belinostat 3Nivolumab 3Etoposide 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3Bortezomib 3Azacitidine 3tazemetostat 2sodium-iodide symporter 2pegaspargase 2merphos 2liposomal doxorubicin 2cemiplimab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell × MAC-ST-001 × Clear all
NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡